泌尿道感染治療市場，依藥物、適應症和地理分類 - 規模、佔有率、前景和機會分析，2024 年至 2031 年

Urinary Tract Infection Therapeutic Market, By Drug, By Indication, and By Geography - Size, Share, Outlook, and Opportunity Analysis, 2024 - 2031

出版日期: 2024年03月11日 | 出版商:

Coherent Market Insights | 英文 197 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計 2024 年全球泌尿道感染治療市場價值為 93.9 億美元，預計在預測期內（2024-2031 年）複合年成長率為 3%。

報告範圍		報告詳情
基準年：	2023年	2023/2024 年市場規模：	93.9 億美元
歷史數據：	2019年至2023年	預測期：	2024年至2031年
預測期間 2023/2024 至 2030/2031 年複合成長率：	3.00%	2030/2031 價值預測：	115.8 億美元

2024 年全球泌尿道感染治療市場價值（十億美元），依地區分類

泌尿道感染 (UTI) 是泌尿系統任何部位的感染。與男性相比，女性罹患泌尿道感染的風險更大。泌尿道感染 (UTI) 通常是由糞便細菌進入泌尿道引起的。抗生素通常是泌尿道感染的首選治療方法。治療單純性泌尿道感染的常用藥物包括甲氧芐啶和磺胺甲噁唑（Bactrim、Bactrim DS）、磷黴素（Monurol）、呋喃妥因（Macrodantin、Macrobid 和 Furadantin）、頭孢氨芐和頭孢曲松。

市場動態：

泌尿道感染的高盛行率、糖尿病和腎結石盛行率的增加、老年人口的增加以及對新型療法開發的關注增加是預計在預測期內推動全球尿路感染治療市場成長的一些主要因素。

2021年10月，Spero Therapeutics Inc.向美國食品藥物管理局（USFDA）提交了新藥申請（NDA），尋求批准氫溴酸替比培南片劑用於治療複雜性泌尿道感染（cUTI），包括腎盂腎炎，此感染由以下原因引起：易感微生物。此外，2021年9月，BDR Pharma推出了比阿培南，用於治療腹內感染、下呼吸道感染或複雜性泌尿道感染患者。

2019 年7 月，美國食品藥物管理局(FDA) 批准了Recarbrio（亞胺培南、西司他丁和瑞巴坦），這是一種抗菌藥物產品，用於治療成人複雜性泌尿道感染(cUTI) 和複雜性腹腔內感染(cIAI)。

研究的主要特點：

該報告對全球尿路感染治療市場進行了深入分析，並提供了預測期（2024-2031）的市場規模和年複合成長率（CAGR%），以2023年為基準年。
它闡明了不同區隔市場的潛在收入機會，並解釋了該市場有吸引力的投資主張矩陣。
這項研究還提供了有關市場促進因素、限制因素、機會、新產品發布或批准、市場趨勢、區域前景以及主要參與者採取的競爭策略的重要見解。
它根據以下參數（例如公司亮點、產品組合、主要亮點、財務表現和策略）介紹了全球尿路感染治療市場的主要參與者。
該報告的見解將使行銷人員和公司管理當局能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
全球尿路感染治療市場報告迎合了該行業的各個利益相關者，包括投資者、供應商、產品製造商、分銷商、新進業者和財務分析師。
利害關係人可以透過用於分析全球尿路感染治療市場的各種策略矩陣輕鬆做出決策。

Report Coverage	Report Details
Base Year:	2023	Market Size in 2023/2024:	US$ 9.39 Bn
Historical Data for:	2019 to 2023	Forecast Period:	2024 to 2031
Forecast Period 2023/2024 to 2030/2031 CAGR:	3.00%	2030/2031 Value Projection:	US$ 11.58 Bn

A urinary tract infection (UTI) is an infection in any part of the urinary system. Women are at greater risk of developing a urinary tract infection compared to men. Urinary tract infections (UTIs) are usually caused by bacteria from poo entering the urinary tract. Antibiotics usually are the first treatment for urinary tract infections. Medicines commonly used for simple UTI s include Trimethoprim and sulfamethoxazole (Bactrim, Bactrim DS), Fosfomycin (Monurol), Nitrofurantoin (Macrodantin, Macrobid, and Furadantin), Cephalexin, and Ceftriaxone.

Market Dynamics:

High prevalence of urinary tract infection, increasing prevalence of diabetes and kidney stones, increasing geriatric population, and increase in focus on the development of novel therapeutics are some major factors expected to drive growth of the global urinary tract infection therapeutic market during the forecast period.

In October 2021, Spero Therapeutics Inc. submitted a new drug application (NDA) to the U.S. Food and Drug Administration (USFDA), seeking approval for tebipenem HBr tablets for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible microorganisms. Moreover, in September 2021, BDR Pharma launched biapenem for the treatment of patients with intra-abdominal infections, lower respiratory infections, or complicated urinary tract infections.

In July 2019, the U.S. Food and Drug Administration (FDA) approved Recarbrio (imipenem, cilastatin and relebactam), an antibacterial drug product to treat adults with complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI).

Key features of the study:

This report provides in-depth analysis of the global urinary tract infection therapeutic market, and provides market size (US$ Billion) and compound annual growth rate (CAGR %) for the forecast period (2024-2031), considering 2023 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global urinary tract infection therapeutic market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Pfizer, Novartis AG, Cipla Inc., Bayer AG, AstraZeneca, Shionogi & Co. Ltd., and GlaxoSmithKline PLC.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global urinary tract infection therapeutic market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global urinary tract infection therapeutic market.

Detailed Segmentation:

Global Urinary Tract Infection Therapeutic Market By Drug:
- Penicillin and Combinations
- Quinolones
- Cephalosporin
- Azoles and Amphotericin B
- Nitrofurans
- Other Drugs
Global Urinary Tract Infection Therapeutic Market By Indication;
- Complicated UTI
- Uncomplicated UTI
- Other Indications
Global Urinary Tract Infection Therapeutic Market By Geography:
- North America
- Europe
- Asia-Pacific
- Middle East and Africa
- South America
Company Profiles:
- Pfizer
- Novartis AG
- Cipla Inc.
- Bayer AG
- AstraZeneca
- Shionogi & Co. Ltd.
- GlaxoSmithKline PLC

Market Dynamics
- High prevalence of urinary tract infection across the globe
- Adverse effects associated with the use of UTI medication
- Increase in focus on the development of novel drugs
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Urinary Tract Infection Therapeutic Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Urinary Tract Infection Therapeutic Market, By Drug, 2019-2031, (US$ Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Penicillin and Combinations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
Quinolones
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
Cephalosporin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
Azoles and Amphotericin B
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
Nitrofurans
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
Other Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)

6. Global Urinary Tract Infection Therapeutic Market, By Indication, 2019-2031, (US$ Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Complicated UTI
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
Uncomplicated UTI
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)
Other Indications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Bn)

7. Global Urinary Tract Infection Therapeutic Market, By Geography, 2019-2031, (US$ Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2019-2031,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019-2031,(US$ Bn)
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2019-2031,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019-2031,(US$ Bn)
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2019-2031,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019-2031,(US$ Bn)
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2019-2031,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019-2031,(US$ Bn)
Middle East and Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2019-2031,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019-2031,(US$ Bn)
Rest of World
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2019-2031,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019-2031,(US$ Bn)

8. Competitive Landscape

Pfizer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Cipla Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Shionogi & Co. Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
GlaxoSmithKline PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies